Skip to main content
SpringerLink
Log in

The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics. 2012;30(11):981–9.

    Article  PubMed  Google Scholar 

  2. van Baal P, Meltzer D, Brouwer W. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. Pharmacoeconomics. 2013. doi:10.1007/s40273-013-0042-9.

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors’ conflicts of interest disclosed in the published paper [1] remain unchanged.

Author information

Authors and Affiliations

  1. Cornerstone Research Group Inc., 204-3228 South Service Road, Burlington, ON, L7N 3H8, Canada

    Daniel T. Grima & Lisa M. Bernard

  2. Genzyme Corporation, Boston, MA, USA

    Elizabeth S. Dunn

  3. St. Michael’s Hospital, Toronto, ON, Canada

    Philip A. McFarlane

  4. Humber River Regional Hospital, Toronto, ON, Canada

    David C. Mendelssohn

Authors
  1. Daniel T. Grima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa M. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth S. Dunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip A. McFarlane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David C. Mendelssohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel T. Grima.

Additional information

This reply refers to the comment available at doi: 10.1007/s40273-013-0042-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grima, D.T., Bernard, L.M., Dunn, E.S. et al. The Authors’ Reply to van Baal et al.: “Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.”. PharmacoEconomics 31, 375–376 (2013). https://doi.org/10.1007/s40273-013-0046-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-013-0046-5

Keywords

Search

Navigation